ProtoKinetix

ProtoKinetix Total Assets

The Total Assets of ProtoKinetix (PKTX) as of Nov 19, 2026 is 483,374.00 USD. In the previous year, Total Assets was 466,137.00 USD — a change of 3.70% (higher).

Total Assets

483,374.00USD

YoY

3.70%

Last updated:

Total Assets of ProtoKinetix is 2025 483,374.00 USD. Total Assets of ProtoKinetix was 2024 466,137.00 USD. It decreases by 3.70% higher compared to the previous year.

The ProtoKinetix Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2018
324,850.00 USD
Jan 1, 2019
585,907.00 USD
Jan 1, 2020
469,181.00 USD
Jan 1, 2021
446,234.00 USD
Jan 1, 2022
462,870.00 USD
Jan 1, 2023
480,557.00 USD
Jan 1, 2024
466,137.00 USD
Jan 1, 2025
483,374.00 USD
The ProtoKinetix Total Assets history
YEARTotal AssetsYoY
483,374.00USD+3.70%
466,137.00USD-3.00%
480,557.00USD+3.82%
462,870.00USD+3.73%
446,234.00USD-4.89%
469,181.00USD-19.92%
585,907.00USD+80.36%
324,850.00USD-37.30%
518,097.00USD-4.43%
542,094.00USD+20.53%
449,752.00USD+7,635.67%
5,814.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ProtoKinetix Stock analysis

What does ProtoKinetix do? ProtoKinetix Inc. is a Canadian biotechnology company focused on the development of glycoproteins for therapeutic applications. The company was founded in 2005 and is headquartered in Marietta, USA. ProtoKinetix specializes in the research and development of AAGP® (Anti-Aging Glycopeptide) as biopharmaceuticals. These proprietary glycoproteins have the ability to protect cells and can be used in various therapeutic applications for improving damage in physical injury, spinal cord injury, diabetes, transplantation, and retinal diseases. In addition to the medical field, ProtoKinetix is also developing its patented technology for use in bio-agriculture and animal healthcare. It has a subsidiary that holds the rights to use and distribute AAGP® and its patents. ProtoKinetix's business model involves licensing its glycoprotein technology for various applications, including biopharmaceuticals, bioprocessing industries, and cell protection management for regenerative medicine and stem cell preparations. The company has established partnerships with other biotech companies to integrate its AAGP® technology into their product pipelines. ProtoKinetix's flagship product is the AAGP® protein solution, which is used as a medication in regenerative medicine, organ transplantation, eye healing, and animal health. It is also interested in researching the application of AAGP® in crop farming to increase yields and improve soil quality. ProtoKinetix is poised to play a significant role in the development of glycoproteins as future medicines and therapeutic technologies in various industries. It not only has the potential to explore healing medical products but also aims to enhance agriculture and animal care. ProtoKinetix represents an excellent example of a biotechnology company focused on improving the healthcare and agricultural industries. ProtoKinetix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ProtoKinetix stock

Total Assets of ProtoKinetix is 483,374.00 USD in 2025.

Total Assets of ProtoKinetix changed from 466,137.00 USD to 483,374.00 USD, representing a 3.70% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets ProtoKinetix since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's ProtoKinetix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — ProtoKinetix

All Key Metrics — ProtoKinetix